Department of Pediatrics, Division of Neonatology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey
Department of Pediatrics, Faculty of Medicine, Dicle University, Diyarbakır, Turkey
Turk J Med Sci. 2021 Aug 30;51(4):1917-1923. doi: 10.3906/sag-2101-295.
BACKGROUND/AIM: Postnatal corticosteroids are commonly used to treat bronchopulmonary dysplasia (BPD). We aimed to show whether S100 calcium-binding B (S100B), neuron-specific enolase (NSE), Tau protein or microtubule-associated protein tau (MAPT), and glial fibrillary acid protein (GFAP) levels would provide any evidence of early neurological damage in premature infants receiving postnatal low dose dexamethasone therapy for BPD treatment.
In this cohort study, 136 preterm infants diagnosed with BPD at ≤32 weeks of gestation formed the study group, and 64 preterm infants formed the control group. NSE, S100B, GFAP, and MAPT levels were first measured before the postnatal corticosteroid treatment in both the patient and the control group on the 28th day and, for a second time, after treatment termination in the patient group.
There were significant differences between the measured GFAP, MAPT, and NSE values of the BPD and control groups on the 28th day, whereas there was no significant difference between the measured S100B values of the two groups. There were a statistically significant difference between the NSE values measured on the 28th day and after the treatment within the BPD group, whereas no significant difference existed between the GFAP, MAPT, and S100B values.
NSE levels, which indicate brain damage in the early period, increased in preterm babies with BPD who had been administered postnatal dexamethasone.
背景/目的： 产后皮质类固醇常用于治疗支气管肺发育不良（BPD）。我们旨在表明 S100 钙结合蛋白 B（S100B）、神经元特异性烯醇化酶（NSE）、Tau 蛋白或微管相关蛋白 Tau（MAPT）和神经胶质纤维酸性蛋白（GFAP）水平是否会为接受产后低剂量地塞米松治疗 BPD 的早产儿提供任何早期神经损伤的证据。
在这项队列研究中，136 名被诊断为≤32 周胎龄 BPD 的早产儿为研究组，64 名早产儿为对照组。在患者和对照组的第 28 天，在接受产后皮质类固醇治疗之前，首次测量了 NSE、S100B、GFAP 和 MAPT 水平，然后在患者组中治疗结束后再次测量。
在第 28 天，BPD 和对照组的 GFAP、MAPT 和 NSE 测量值之间存在显著差异，而两组的 S100B 测量值之间无显著差异。BPD 组第 28 天和治疗后 NSE 值之间存在统计学显著差异，而 GFAP、MAPT 和 S100B 值之间无显著差异。
在接受产后地塞米松治疗的患有 BPD 的早产儿中，NSE 水平（表明早期脑损伤）增加。
